pharma

Safety Data Exchange Agreements (SDEAs) and PV Arrangements with External Vendors MasterClass - US edition

09-10 November, 2026

09-10 November, 2026Virtual

This should also be considered in all outsourced activities of a pharmaceutical company that may lead to any capture of safety information related to the products of which the company is the Marketing Authorization Holder (MAH).

09-10 November, 2026, Virtual
Time Zone: Eastern Daylight Time (EDT) - UTC04:00

Key learnings

Assure Safety Information

How to Assure that all Safety Information is Captured and Collected in the Safety Databases.

Definition of Responsibilities

Definition of Responsibilities by all Parties.

Regulatory Authorities

Dealing with the Regulatory Authorities and meeting FDA requirements

Timely Reporting

How to Assure that any Outsourced Activity Allows Collection and Timely Reporting of all Safety-Related Information.

Safety Information

Adequate Collection, Processing and Timely Reporting of Safety Information by all Parties.

Trusted by over 17,000 delegates across leading companies

PartnerPartnerPartnerPartnerPartnerPartnerPartnerPartnerPartnerPartnerPartnerPartner

Overview

It is common in our globalized world that, according to their specific strengths and interests more than one pharmaceutical is involved in the marketing of a pharmaceutical product, even in the same geographical area or country. It is crucial and tightly required by the Regulatory Authorities that the safety information arising at any point is adequately captured, distributed, and adequately and timely reported. The risk-benefit ratio should be maintained at all times and for this reason, agreements between pharmaceutical companies marketing a certain product should include agreements (so-called Safety Data Exchange Agreements, SDAE) to ensure the adequate flow of any arising safety concerns.

This should also be considered in all outsourced activities of a pharmaceutical company that may lead to any capture of safety information related to the products of which the company is the Marketing Authorization Holder (MAH)

#masterclass     #glceurope      #pharmaonlinetraining      #globalleadingconferences       #USsafetydataagreements      #pharmacovigilance     #externalvendors

Explore more

Meet the expert

Trainer

Joan Francesc Aregall Picamal

Joan Francesc Aregall Picamal

PHARMACOVIGILANCE CONSULTANT & DRUG SAFETY & SDEA SPECIALIST

Joan Francesc Aregall is a Pharmacist with and MBA in Pharmaceutical Industry by the Barcelona University. More than 30-year experience in several pharmaceutical companies. First in Regulatory Affairs (for more than 15 years), after sharing Regulatory Affairs and Pharmacovigilance and finally fully devoted to Pharmacovigilance and Safety of Pharmaceutical Products both marketed and under Clinical Development.

In 2016 decided to establish himself as a free-lance and took PV auditing courses at the Research Quality Association (RQA). Since 2012, has been actively participating as a Member of the Spanish Association of Industry Pharmacists as a trainer of different and speaker of PV courses.

Reasons to attend a masterclass

Practical knowledge

Venture into undiscovered territories and gain inspiration through collaboration

Interactivity

Boost your professional skills by directly engaging with domain experts

World-class trainers

Gain value and learn from the best instructors

Networking

Build a top-notch community and advance your career

Who should attend imgWHO SHOULD ATTEND

-Pharmacovigilance professionals
-Auditors and PV Auditors
-Medical Affairs Professionals involved in outsourced Medical Activities as Advisory Boards, Congresses, etc
-Marketing Professionals working in outsourcing activities
-Legal Department Professionals

Ticket options for you

Looking for an in-house training?

*minimum of 10 participants
Learn more
14+

Years of experience

600+

Events organized

4,000+

Speakers

25,000+

Attendees

Take the next step

REQUEST AGENDA FORM

Impressions

  • SDEA